7 results about "Letrozole" patented technology

This invention discloses the use of letrozole or its pharmaceutically acceptable salts, solvates, or hydrates in the preparation of medicaments for treating lymphoma. Experimental verification has shown that letrozole or its pharmaceutically acceptable salts, solvates, or hydrates can be used to treat lymphoma, particularly diffuse large B-cell lymphoma with c-MYC rearrangements.

Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+ / HER2−) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.

The application provides use of CYP2A6 genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy for breast cancer, patients with CYP2A6 intermediate / slow metabolism type are more likely to achieve pCR than patients with normal metabolism type, CYP2A6 rs61663607 T>C TT type is more likely to achieve pCR than TC and CC types, in patients with neoadjuvant chemotherapy combined with or without letrozole, CYP2A6 rs7250713 G>C CC type is more likely to achieve pCR than CC and CG types. The application also provides use of CYP2A6 genotype in preparation of a reagent for diagnosing and predicting the efficacy of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy for breast cancer. The application is used for auxiliary diagnosis of the efficacy of neoadjuvant chemotherapy combined with or without letrozole treatment for early hormone receptor positive breast cancer patients receiving neoadjuvant therapy and surgery.

Methods for treating gliomas, such as glioblastoma, including administering an aromatase inhibitor, such as letrozole, to a subject suffering from a glioma. The method may further include administering the aromatase inhibitor in combination with a poly-ADP ribose polymerase inhibitor, such as olaparib, pamiparib, veliparib or niraparib.

The invention relates to an induction method and feed for XX type pseudo male fishes of Atlantic salmon and application of the induction method and the feed, and belongs to the technical field of aquaculture breeding, the method comprises the following steps: when genetic female fish fries of Atlantic salmon open mouths for ingestion, 17 alpha-methyltestosterone or letrozole is fed every day, the feeding time duration is greater than or equal to 60 days, and the XX type pseudo male fishes are obtained. The invention also provides a feed containing 17 alpha-methyltestosterone or letrozole and application of the feed to culture of pseudo male Atlantic salmon. According to the invention, the effective window period is accurately shortened to the 60th day from the beginning of exogenous ingestion to ingestion, and the induction success rate of 1.5-4.5 mg / kg of 17 alpha-methyltestosterone can reach 100%; the induction success rate of 150 mg / kg letrozole is 80%, the induction success rate of 200 mg / kg letrozole is 83%, and the induction success rate of 250 mg / kg letrozole is 100%.